Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise
Sciwind Biosciences Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, seeking...
Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise
Sanofi S.A. (NASDAQ: SNY) announced that Dupixent (dupilumab) has received marketing approval from Japan’s Ministry...
Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...
IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma
IASO Biotherapeutics announced receiving tacit clinical approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
Kelun‑Biotech Reports 2025 Revenue RMB 2.06 Billion – Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification
Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full‑year revenue...
Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China
Hope Medicine Inc. announced first patient dosing in a Phase III clinical study evaluating HMI-115,...
Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors
Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its SKB103, a novel TAA‑PD‑L1 bispecific...
Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating...
Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer
Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study of...
Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
Keymed Biosciences Inc. (HKG: 2162) announced that its NewCo partner Ouro Medicines has entered into...
Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced clinical trial approval from China’s National Medical...
Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Roche (SWX: ROG, OTCMKTS: RHHBY) announced the inauguration of the new research home for the...
Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases
Kali Therapeutics announced a licensing agreement with Sanofi (NASDAQ: SNY) for KT501, a novel trispecific...
GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses
GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received...
Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market
Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (HKG: 0512) announced an exclusive...
Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market
Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly...
Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic
Sinomune Pharmaceutical Co., Ltd., a China-based dermatological specialist, announced a licensing agreement with Almirall, S.A....
Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced a licensing agreement with Nizhny Novgorod Chemical...
Tenacia Bio Licenses Ztalmy to Golden Age Health – Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China
Tenacia Biopharmaceuticals (Shanghai) Co., Ltd., a Bain Capital-incubated CNS specialist, announced a licensing agreement with...
Formosa Pharmaceuticals Licenses APP13007 to Arrotex – Nanoparticle Ophthalmic Steroid Gains Australia/New Zealand Rights
Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Arrotex Pharmaceuticals Pty Ltd., granting the...